Literature DB >> 26028476

Ovarian and oocyte targets for development of female contraceptives.

Satish Kumar Gupta1, Ankita Malik2, Ananta Prasad Arukha3.   

Abstract

INTRODUCTION: Steroid hormone-based contraceptives have been used by women for long time since their introduction. Efforts have been made to make steroidal contraceptives cost-effective, safe and improve their users' compliance. In addition, attempts have been made to develop nonsteroidal contraceptives. Contraceptive vaccines have been investigated as an alternate strategy for contraception. AREAS COVERED: The currently used steroidal contraceptives are reviewed. In addition, status of emerging nonsteroidal contraceptives that inhibit folliculogenesis, oocyte maturation, ovulation and endometrium receptivity targeting phosphodiesterase 3, angiopoietins, gonadotropin-releasing hormone, COX-2, progesterone/estrogen receptor and follicle-stimulating hormone receptor are presented. Various approaches to develop contraceptive vaccines aiming to inhibit ovarian follicle development, ovulation, fertilization and implantation including their current applications and limitations are discussed. EXPERT OPINION: Development of new nonsteroidal contraceptives, in addition to long-acting steroidal contraceptives, is pertinent for offering wider choice to women. It is imperative that basic research to discover new targets in the ovaries must be undertaken to facilitate development of novel contraceptives. Further, efforts on studying the feasibility and safety of contraceptive vaccines may be continued to bring these within the realm of application as contraceptives for humans.

Entities:  

Keywords:  COX-2 inhibitor; PDE3 inhibitor; anti-angiogenic agent; contraceptive vaccines; estrogen receptor modulator; follicle-stimulating hormone receptor; gonadotropin-releasing hormone; human chorionic gonadotropin; progesterone receptor modulator; steroid hormone-based contraceptives; zona pellucida

Mesh:

Substances:

Year:  2015        PMID: 26028476     DOI: 10.1517/14728222.2015.1051305

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  2 in total

1.  AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.

Authors:  Motohiro Kano; Amanda E Sosulski; LiHua Zhang; Hatice D Saatcioglu; Dan Wang; Nicholas Nagykery; Mary E Sabatini; Guangping Gao; Patricia K Donahoe; David Pépin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

2.  In silico Docking Analysis for Blocking JUNO-IZUMO1 Interaction Identifies Two Small Molecules that Block in vitro Fertilization.

Authors:  Nataliia Stepanenko; Omri Wolk; Enrica Bianchi; Gavin James Wright; Natali Schachter-Safrai; Kiril Makedonski; Alberto Ouro; Assaf Ben-Meir; Yosef Buganim; Amiram Goldblum
Journal:  Front Cell Dev Biol       Date:  2022-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.